#Japan #Tokyo #THE PHAGE #Fukui Capital Partners #Glucose Flight

THE PHAGE Secures New Funding

THE PHAGE, a Tokyo-based company specializing in healthcare innovations, has successfully raised capital from Fukui Capital Partners (FCP) through their venture fund, minori. This marks the second investment by the fund, aiming to bolster the company's ongoing projects in health management applications, primarily through their flagship app, Glucose Flight.

Investment Overview

The investment comes from FCP, which leads the Fukui startup support program and represents the second funding initiative under the minori fund. Although the exact amount of the investment remains confidential, the support emphasizes FCP's confidence in THE PHAGE's mission to revolutionize healthcare through data utilization.

Background of the Funding

In February 2025, THE PHAGE entered into a collaborative agreement with Fukui Prefecture, aimed at leveraging AI to promote data health and advance digital transformation in the healthcare sector. With over 4,000 residents having used the Glucose Flight application, the company has made significant strides in raising health awareness and managing lifestyle-related disease risks across the community.

FCP’s investment is a testament to their belief in THE PHAGE’s approach to addressing rising healthcare costs through innovative solutions and collaborations with local authorities.

About Glucose Flight

Glucose Flight is a health management service application that collaborates with Continuous Glucose Monitoring (CGM) devices. The app accurately tracks fluctuations in post-meal blood sugar levels based on dietary intake, providing users with personalized recommendations for nutrition and exercise to mitigate disease risks. Traditionally, healthcare for diabetes management has often been one-size-fits-all; however, Glucose Flight offers personalized insights that cater to individual needs, enhancing support and treatment possibilities for every user.

By applying the expertise gained from blood sugar data analysis to other biometric data, THE PHAGE aims to prevent the onset and worsening of various lifestyle diseases, promoting a healthier and more prosperous society.

Perspective from Leadership

Shohei Tokunaga, CEO of THE PHAGE, expressed optimism regarding the recent funding. "This investment will strengthen our collaborations in Fukui Prefecture and enhance our data health initiatives and healthcare DX through AI research. Our goal is to contribute to extending the healthy life expectancy of citizens and achieving a sustainable social security system. We welcome professionals who share our vision to participate in these advancements."

For more information about THE PHAGE and current job openings, including positions in Data Science, Web and Mobile Engineering, Product Management, and Clinical Affairs, please visit their website at THE PHAGE.

Contact Information

For inquiries about this press release, please reach out to the public relations team at [email protected].